The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Table 2

Adjusted Cox regression for OS and PFS before PSM, adjusted for age, ALT, AST, hemoglobin, platelet, lymphocytes, neutrophils, tumor size, gender, HBV infection, AFP level, TACE session, tumor number, portal invasion, extrahepatic metastases, cirrhosis, Child-Pugh, and ECOG.

Characteristics	Overall survival		Progression-free survival
	HR (95%CI)	value	HR (95%CI)	value
Overall
TACE-S	Reference	0.620	Reference	0.589
TACE-A	0.908 (0.620,1.330)		0.906 (0.634,1.295)
Before 12-month Landmark
TACE-S	Reference	0.744	Reference	0.601
TACE-A	1.086 (0.663,1.780)		0.906 (0.624,1.314)
Before 12-month Landmark
TACE-S	Reference	0.200	Reference	0.036
TACE-A	0.627 (0.307,1.281)		0.044 (0.002,0.810)

Abbreviations: TACE-S: transarterial chemoembolization combined with sorafenib; TACE-A: transarterial chemoembolization combined with apatinib.